Olivier BOHUON appointed Chief Executive Officer of Pierre Fabre SA

Olivier BOHUON appointed Chief Executive Officer of Pierre Fabre SA


CASTRES, France, September 1, 2010/PRNewswire/ -- During its first meeting, the Board of Directors of Pierre Fabre SA chaired by Mr. Pierre Fabre appointed Olivier BOHUON as the company's Chief Executive Officer.


Olivier BOHUON, 51, has until now been the executive vice-president of Abbott Corporation and president of its pharmaceutics division. In this capacity, he directed the group's entire pharmaceutical business (22 billion dollars turnover) from Chicago. He also became group president for Europe in 2003 and subsequently president of Abbott international.
 

Olivier BOHUON has also been appointed president of Pierre Fabre Medicament as of today.
 

About the Pierre Fabre group
 

The Pierre Fabre group, owned on a majority basis by a public utility Foundation, is France's second largest independent pharmaceutics laboratory and the leader in cosmetics products sold in pharmacies.
 

It employs a workforce of nearly 10,000 including 1,400 in research.
 

In 2009, the Pierre Fabre group achieved a turnover of 1.8 billion EUR and dedicated 28% of its medical turnover to research and development in three main therapeutic areas: oncology, central nervous system, dermatology and cardio-vascular/metabolism.
 

To find out more about Laboratoires Pierre Fabre : http://www.pierre-fabre.com
 

Source: Groupe Pierre Fabre

Press contacts: Djamila Hazene-Kedjem: +33(0)1-49-10-81-12, +33(0)6-89-45-87-95, [email protected]

 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.